Chung Shan Medical University

Taichung 402306

3 studies enrolling now · 9 studies all time

What they study most

ALK-positive Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase-positive, Hemophilia B, Hemophilia B with Inhibitor, Hemophilia a, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC), Resectable Non-small Cell Lung Cancer, Spondylitis, Ankylosing

Studies at this site

• Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC — Recruiting now
• Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors — Available (expanded access)
• Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors — Available (expanded access)
• A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B — Running, not enrolling
• A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery — Running, not enrolling
• A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors — Stopped early
• Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5) — Stopped early
• A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label — Stopped early
• Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA — Completed